NCT06341907View on ClinicalTrials.gov

Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Epithelial Ovarian Cancer
Interventions
BIOLOGICAL

Neoantigen polypeptide vaccine

Completion of polypeptide neoantigen polypeptide vaccine (day 1, 4, 8, 15, 22, 54, and 84)

Trial Locations (1)

325000

RECRUITING

Second Affiliated Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Wenzhou Medical University

OTHER